Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women (FLAG)
Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman
Sponsor: Asan Medical Center
This PHASE2 trial investigates Breast Cancer Nos Premenopausal and Estrogen Receptor Positive Tumor and is currently ongoing. Asan Medical Center leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Jun 2017 [monthly]
Unknown Status PHASE2
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asan Medical Center
- Korea University Anam Hospital
- Korea University Guro Hospital
- Kosin University Gospel Hospital
- Samsung Medical Center
- Seoul National University Hospital
- Severance Hospital
- Ulsan University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .